"Widespread use of GLP-1 weight loss drugs to treat obesity could reduce cumulative all-cause mortality by up to 6.4% in the US and 5.1% in the UK general populations by 2045 ... GLP-1 drugs may reshape claims experience across mortality, longevity and medical insurance products.... In the US and UK general populations, [the] modelled baseline scenario projects 4% and 3.2% reductions in cumulative all-cause mortality respectively by 2045, based on GLP-1 drug use."  MORE >>